FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1863225814> ?p ?o ?g. }

• W1863225814 endingPage "106" @default.
• W1863225814 startingPage "106" @default.
• W1863225814 abstract "PURPOSE: To assess progression-free survival (PFS) and overall survival (OS) in patients with suboptimally debulked epithelial ovarian cancer receiving cisplatin (100 mg/m 2 ) or 24-hour infusion paclitaxel (200 mg/m 2 ) or the combination of paclitaxel (135 mg/m 2 ) followed by cisplatin (75 mg/m 2 ). PATIENTS AND METHODS: After stratification for disease measurability, patients were randomized to receive six cycles of one of the treatments every 3 weeks. If measurable, complete response (CR) or partial response (PR) was determined. RESULTS: Six hundred fourteen of 648 patients who entered onto the trial were eligible. Monotherapies were discontinued more frequently (cisplatin because of toxicity or patient refusal [17%], and paclitaxel because of progression [20%]) compared with the combination therapy (7% and 6%, respectively). Neutropenia, fever, and alopecia were more severe with paclitaxel-containing regimens; whereas anemia, thrombocytopenia, neurotoxicity, nephrotoxicity, and gastrointestinal toxicity were more severe with cisplatin-containing regimens. The CR/PR rates on paclitaxel monotherapy were significantly lower compared with the cisplatin regimens (42% v 67%, respectively; P < .001). The relative hazard (RH) of first progression or death was significantly greater among those randomized to paclitaxel (RH = 1.41; 95% confidence interval [CI], 1.15 to 1.73; P < .001) when compared with cisplatin; however, RH did not differ significantly between the two cisplatin regimens (RH = 1.06; 95% CI, 0.895 to 1.30). Relative to cisplatin, the death rate on paclitaxel was 15% greater (RH = 1.15; 95% CI, 0.929 to 1.42), and the death rate on the combination treatment was 1% less (RH = 0.99; 95% CI, 0.795 to 1.23). These differences among treatment groups were not statistically significant (P = .31). CONCLUSION: Cisplatin alone or in combination yielded superior response rates and PFS relative to paclitaxel. However, OS was similar in all three arms, and the combination therapy had a better toxicity profile. Therefore, the combination of cisplatin and paclitaxel remains the preferred initial treatment option." @default.
• W1863225814 created "2016-06-24" @default.
• W1863225814 creator A5002181160 @default.
• W1863225814 creator A5009816072 @default.
• W1863225814 creator A5015735346 @default.
• W1863225814 creator A5043240282 @default.
• W1863225814 creator A5051551564 @default.
• W1863225814 creator A5053891169 @default.
• W1863225814 creator A5063378114 @default.
• W1863225814 creator A5077857437 @default.
• W1863225814 creator A5082042139 @default.
• W1863225814 date "2000-01-01" @default.
• W1863225814 modified "2023-10-14" @default.
• W1863225814 title "Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study" @default.
• W1863225814 cites W1758230404 @default.
• W1863225814 cites W1827936231 @default.
• W1863225814 cites W1981534406 @default.
• W1863225814 cites W2003428752 @default.
• W1863225814 cites W2014935377 @default.
• W1863225814 cites W2028453672 @default.
• W1863225814 cites W2097239572 @default.
• W1863225814 cites W2107003788 @default.
• W1863225814 cites W2129678716 @default.
• W1863225814 cites W2141258764 @default.
• W1863225814 cites W219610197 @default.
• W1863225814 cites W2260361758 @default.
• W1863225814 cites W2261061437 @default.
• W1863225814 cites W2271324119 @default.
• W1863225814 cites W2328421677 @default.
• W1863225814 cites W2411463560 @default.
• W1863225814 cites W3147894994 @default.
• W1863225814 cites W4210704032 @default.
• W1863225814 cites W4293241248 @default.
• W1863225814 doi "https://doi.org/10.1200/jco.2000.18.1.106" @default.
• W1863225814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10623700" @default.
• W1863225814 hasPublicationYear "2000" @default.
• W1863225814 type Work @default.
• W1863225814 sameAs 1863225814 @default.
• W1863225814 citedByCount "554" @default.
• W1863225814 countsByYear W18632258142012 @default.
• W1863225814 countsByYear W18632258142013 @default.
• W1863225814 countsByYear W18632258142014 @default.
• W1863225814 countsByYear W18632258142015 @default.
• W1863225814 countsByYear W18632258142016 @default.
• W1863225814 countsByYear W18632258142017 @default.
• W1863225814 countsByYear W18632258142018 @default.
• W1863225814 countsByYear W18632258142019 @default.
• W1863225814 countsByYear W18632258142020 @default.
• W1863225814 countsByYear W18632258142021 @default.
• W1863225814 countsByYear W18632258142022 @default.
• W1863225814 countsByYear W18632258142023 @default.
• W1863225814 crossrefType "journal-article" @default.
• W1863225814 hasAuthorship W1863225814A5002181160 @default.
• W1863225814 hasAuthorship W1863225814A5009816072 @default.
• W1863225814 hasAuthorship W1863225814A5015735346 @default.
• W1863225814 hasAuthorship W1863225814A5043240282 @default.
• W1863225814 hasAuthorship W1863225814A5051551564 @default.
• W1863225814 hasAuthorship W1863225814A5053891169 @default.
• W1863225814 hasAuthorship W1863225814A5063378114 @default.
• W1863225814 hasAuthorship W1863225814A5077857437 @default.
• W1863225814 hasAuthorship W1863225814A5082042139 @default.
• W1863225814 hasConcept C121608353 @default.
• W1863225814 hasConcept C126322002 @default.
• W1863225814 hasConcept C126894567 @default.
• W1863225814 hasConcept C143998085 @default.
• W1863225814 hasConcept C207103383 @default.
• W1863225814 hasConcept C2776694085 @default.
• W1863225814 hasConcept C2777063308 @default.
• W1863225814 hasConcept C2777292972 @default.
• W1863225814 hasConcept C2778239845 @default.
• W1863225814 hasConcept C2780427987 @default.
• W1863225814 hasConcept C2780435969 @default.
• W1863225814 hasConcept C2780739268 @default.
• W1863225814 hasConcept C29730261 @default.
• W1863225814 hasConcept C44249647 @default.
• W1863225814 hasConcept C71924100 @default.
• W1863225814 hasConcept C90924648 @default.
• W1863225814 hasConceptScore W1863225814C121608353 @default.
• W1863225814 hasConceptScore W1863225814C126322002 @default.
• W1863225814 hasConceptScore W1863225814C126894567 @default.
• W1863225814 hasConceptScore W1863225814C143998085 @default.
• W1863225814 hasConceptScore W1863225814C207103383 @default.
• W1863225814 hasConceptScore W1863225814C2776694085 @default.
• W1863225814 hasConceptScore W1863225814C2777063308 @default.
• W1863225814 hasConceptScore W1863225814C2777292972 @default.
• W1863225814 hasConceptScore W1863225814C2778239845 @default.
• W1863225814 hasConceptScore W1863225814C2780427987 @default.
• W1863225814 hasConceptScore W1863225814C2780435969 @default.
• W1863225814 hasConceptScore W1863225814C2780739268 @default.
• W1863225814 hasConceptScore W1863225814C29730261 @default.
• W1863225814 hasConceptScore W1863225814C44249647 @default.
• W1863225814 hasConceptScore W1863225814C71924100 @default.
• W1863225814 hasConceptScore W1863225814C90924648 @default.
• W1863225814 hasIssue "1" @default.
• W1863225814 hasLocation W18632258141 @default.
• W1863225814 hasLocation W18632258142 @default.
• W1863225814 hasOpenAccess W1863225814 @default.
• W1863225814 hasPrimaryLocation W18632258141 @default.

• next